title: Myelodysplasia occurring after fludarabine treatment for chronic lymphocytic leukaemia.
abstract: The purine analogue, fludarabine, is of proven efficacy in the treatment of lymphoid malignancies. The drug appears to be well tolerated with minimal side-effects, and few toxicities have been observed. A case of myelodysplasia occurring after therapy with fludarabine is presented and its implications are discussed.
authors.affiliation: Department of Haematology, Southampton University Hospitals NHS Trust, UK.
authors.forename: R J
authors.initials: RJ
authors.lastname: Frewin
authors.forename: D
authors.initials: D
authors.lastname: Provan
authors.forename: A G
authors.initials: AG
authors.lastname: Smith
mesh_terms: D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use* / Q000633:toxicity*; D002898:Chromosomes, Human, Pair 8; D005500:Follow-Up Studies; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000188:drug therapy*; D008297:Male; D009190:Myelodysplastic Syndromes / Q000139:chemically induced*; D009503:Neutropenia / Q000139:chemically induced; D013921:Thrombocytopenia / Q000139:chemically induced; D014314:Trisomy / Q000235:genetics; D014740:Vidarabine / Q000031:analogs & derivatives* / Q000627:therapeutic use / Q000633:toxicity
chemical_list: D000970:Antineoplastic Agents; D014740:Vidarabine; C024352:fludarabine